Suspicion lingers over bisphenol A and breast cancerAugust 28, 2006BLOOMINGTON, Ind. - Bisphenol A, a common industrial chemical claimed to speed the growth of human breast and ovarian cancers, retains its carcinogenic properties even after being modified by body processes, report Indiana University and University of California at Berkeley scientists in the Aug. 28th issue of Chemistry & Biology, a Cell Press journal. Defenders of bisphenol A's use have argued that its natural modification inside the human body renders the estrogen-like chemical harmless. "We tested whether this chemical modification - the addition of sulfate to BPA - keeps the chemical from being absorbed by breast tumor cells," said IU Bloomington biochemist Theodore Widlanski, who led the project. "We've shown that modified versions of bisphenol A likely to be formed in the body do stimulate breast tumor cell growth in vitro. Enzymes present on the surface of breast tumor cells appear to convert the modified BPA back into BPA." BPA is a plasticizer present at low levels in mineral water bottles, CDs and DVDs, car parts and other household products. A recent U.S. Center for Disease Control and Prevention study found trace amounts of BPA in 95 percent of urine samples collected from American adults. The researchers present a model for the selective uptake of BPA into breast cancer cells by implicating human enzymes that sulfate and de-sulfate BPA. One of those enzymes, estrogen sulfotransferase, adds sulfate to estrogen, making the molecule water soluble and easily transportable through the bloodstream. Widlanski's collaborators showed that BPA, too, can be sulfated by estrogen sulfotransferase. Breast cancer cells are known to overproduce an enzyme that other, healthier cells don't - aryl sulfatase C. Aryl sulfatase C removes sulfate from estrogen, allowing the hormone's absorption into cells. In the present Chemistry & Biology paper, Widlanski's group shows aryl sulfatase C can also de-sulfate BPA, and that the concentration of non-sulfated BPA inside breast cancer cells goes up when the cells are grown in a medium containing sulfated BPA. That human enzymes are capable of the sulfation and desulfation of BPA suggests breast cancer cells are a lightning rod not only for natural estrogen, but for BPA too, Widlanski said. Widlanski cautions those who would misinterpret the results of the study. "We have not shown this process takes place in vivo," he said. "We have only demonstrated a possible mechanism that explains what people have been speculating about for years. It doesn't mean that your bottled water is any less safe today than it was yesterday. It just means that if it isn't safe, we might be able to explain why." Widlanski said that he has always been a skeptic of claims that BPA causes or speeds the development of cancer and birth defects. "All along we set out to show the opposite - that BPA is not harmful. If any of the answers to our questions had been 'no,' then we would have concluded BPA was not dangerous. But we can't do that, or we can't do it yet." The researchers subjected cancer cells and enzymes to extremely high concentrations of BPA and BPA derivatives - levels not ordinarily experienced by human beings. Widlanski said his group did this in order to simulate the cumulative effects of low BPA concentrations of the course of a human lifetime. "If our hypothesis is true about BPA, it's probably going to be the sum of effects of a lot of cancer-causing compounds that is responsible for the disease," Widlanski said. "We would not anticipate that BPA or any other single chemical is the only culprit here." Indiana University |
|||||||||||||||||||||
| Related Breast Cancer Current Events and Breast Cancer News Articles Menopause-cardiology consensus statement on cardiovascular disease and on HRT A menopause-cardiology consensus statement has called for direct action to prevent cardiovascular disease (CVD) in menopausal women. The statement also concludes that there is little evidence of increased CVD risk in taking HRT. Researchers Identify Role of Gene in Tumor Development, Growth and Progression Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine researchers have identified a gene that may play a pivotal role in two processes that are essential for tumor development, growth and progression to metastasis. UCLA researchers create 'fly paper' to capture circulating cancer cells Just as fly paper captures insects, an innovative new device with nano-sized features developed by researchers at UCLA is able to grab cancer cells in the blood that have broken off from a tumor. Fertility procedures need not delay breast cancer treatment for younger women A new study published in the November issue of the Journal of the American College of Surgeons shows that breast cancer patients under 40 years old who undergo fertility preservation do not face a significant delay in the treatment of their disease when their care is coordinated in a timely fashion. Coffee break: Compound brewing new research in colon, breast cancer A compound in coffee has been found to be estrogenic in studies by Texas AgriLife Research scientists. Drugs to treat anemia in cancer patients linked to thromboembolism Medications frequently given to cancer patients to reduce their risk of anemia are associated with an increased risk of deep vein thrombosis or pulmonary embolism, according to new research led by Dawn Hershman, M.D, M.S., co-director of the breast cancer program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center. Discovery in worms by Queen's researchers points to more targeted cancer treatment Researchers at Queen's University have found a link between two genes involved in cancer formation in humans, by examining the genes in worms. The groundbreaking discovery provides a foundation for how tumor-forming genes interact, and may offer a drug target for cancer treatment. FDA approved leukemia drugs shows promise in ovarian cancer cells The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found. Carnegie Mellon researchers link health-care debate to risk of dying in US and Europe The current health care debate in the United States is complicated. Trade-offs between heath care expenditures, lifestyle choices and life expectancy have been suggested but seldom clearly demonstrated. Scientists uncover new key to the puzzle of hormone therapy and breast cancer The use of postmenopausal hormone therapy has decreased over time in the United States, which researchers suggest may play a key role in the declining rate of atypical ductal hyperplasia, a known risk factor for breast cancer. More Breast Cancer Current Events and Breast Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||